Subject: night blindness/polycythemia
Acta Ophthalmol Scand 2000 Feb;78(1):53-7
Impaired dark adaptation in polycythemia. Improvement after treatment.
Havelius U, Berglund S, Falke P, Hindfelt B, Krakau T
Department of Ophthalmology, Internal Medicine, University Hospital
MAS, University of Lund, Malmo, Sweden. Ulf.Havelius@oftal.mas.lu.se
PURPOSE: To determine if dark adaptation is reduced in individuals
with polycythemia and if so whether there is any improvement in dark
adaptation after treatment. METHODS: Dark adaptation was recorded
monocularly by automatic dark adaptometry in ten consecutive patients
with polycythemia before and after treatment. Analogue investigations
were performed in 31 healthy control subjects. RESULTS: Dark
adaptation was markedly impaired in the patients as compared with the
control subjects. After reduction of the red cell count and
normalization of the hematocrit and hemoglobin the dark adaptation was
markedly improved. There was no significant change in dark vision in
the control subjects negating a confounding learning effect.
CONCLUSION: The findings indicate a sustained but reversible neuronal
hypofunction secondary to polycythemia. As the rheological abnormality
was normalized, dark adaptation was improved, probably secondary to
normalized microcirculation within the retina or the brain, or both,
possibly with reactivation of formerly inactive neuronal cells.
PMID: 10726790, UI: 20189324
_________________________________________________________________
Save the above report in [Macintosh] [Text] format
Order documents on this page through Loansome Doc
_________________________________________________________________
Subject: IRON/GLUCOSE-6-PHOSPHATE DEHYDROGENASE
_________________________________________________________________
Biochim Biophys Acta 1245: 359-365 (1995)[96125732]
Oxidative damage of bovine serum albumin and other enzyme proteins by
iron-chelate complexes.
T. Ogino & S. Okada
Department of Pathology, Okayama University Medical School, Japan.
Direct oxidative protein damage by iron-nitrilotriacetate (NTA), as
well as physiological iron complexes, iron-citrate and iron-ADP was
studied in the presence or absence of H2O2, using bovine serum albumin
(BSA), glucose-6-phosphate dehydrogenase (G-6-PD), glutathione
reductase (GSSGRase) and catalase as the target proteins. Both
Fe(III)NTA+H2O2 and Fe(II)NTA+H2O2 caused marked BSA fragmentation
which accompanied the decrease in the intrinsic tryptophan
fluorescence and appearance of bityrosine fluorescence. However,
Fe(III)citrate+H2O2 showed only slight BSA fragmentation. In the
absence of H2O2, Fe(II) NTA but not Fe(III)NTA caused similar but
slight BSA fragmentation, which depended on the molecular oxygen.
Fe(II)citrate also showed O2-dependent BSA fragmentation to a
comparable degree, however, Fe(II)ADP showed no detectable BSA damage.
BSA fragmentation by Fe(II)NTA+O2 and by Fe(III)NTA+H2O2 resulted in
the appearance of the new alpha-amino groups. Electron spin resonance
study using 5,5-dimethyl-1-pyrroline N-oxide (DMPO) as a spin trapping
reagent showed DMPO-OH spin adduct, which suggests the presence of
hydroxyl radical, in Fe(III)NTA+H2O2, but not in Fe(II)NTA+O2 system.
Fe(II)NTA inactivated G-6-PD and GSSGRase in a O2-dependent manner,
however, G-6-PD was more susceptible to the damage. This enzyme
inactivation also accompanied the protein fragmentation and was not
due to simple sulfhydryl oxidation. Catalase was not significantly
inactivated nor fragmented by Fe(II)NTA+O2. These findings suggest
that the interaction between proteins and iron-chelate complexes is
important in iron catalyzed oxidative damage, and that the structure
of the chelating agent may determine the target molecules.
MeSH Terms:
* Animal
* Catalase/metabolism
* Cattle
* Cyclic N-Oxides
* Electron Spin Resonance Spectroscopy
* Free Radicals
* Glucosephosphate Dehydrogenase/metabolism
* Glutathione Reductase/metabolism
* Iron Chelates/metabolism
* Oxidative Stress
* Serum Albumin, Bovine/metabolism
* Spin Trapping
Substances:
* Catalase
* Glucosephosphate Dehydrogenase
* Glutathione Reductase
* Serum Albumin, Bovine
* Iron Chelates
* Cyclic N-Oxides
* Free Radicals
* 5,5-dimethyl-1-pyrroline-1-oxide
_________________________________________________________________
JAMA 233: 1184-8 (1975)[76007893]
Genetic disorders of human red blood cells.
E. Beutler
Human red blood cells (RBCs) are subject to an enormous degree of
genetic diversity. The variability that occurs may result in anemia,
cyanosis, polycythemia, or may cause no hematologic alterations.
Genetic abnormalities affecting hemoglobin include the sickling
disorders, the unstable hemoglobinopathies, hemoglobinopathies
associated with polycythemia or with methemoglobinemia, and the alpha-
and beta-thalassemias. The most common enzymatic abnormality of RBCs
is glucose-6-phosphate dehydrogenase deficiency, but defects of many
other enzymes leading to hemolytic anemia have been identified.
Deficiences of RBC enzymes may also be important in the diagnosis of
nonhematologic disease and in the evaluation of dietary status.
MeSH Terms:
* Anemia, Hemolytic, Congenital/enzymology
* Anemia, Hemolytic, Congenital/genetics
* Anemia, Hypochromic/diagnosis
* Diagnosis, Differential
* Erythrocytes/enzymology
* Genetic Counseling
* Glucosephosphate Dehydrogenase Deficiency/genetics
* Glycolysis
* Heinz Bodies
* Hemoglobinopathies/genetics
* Hemoglobins, Abnormal/analysis
* Heterozygote
* Homozygote
* Human
* Support, U.S. Gov't, P.H.S.
* Thalassemia/diagnosis
* Thalassemia/genetics
_________________________________________________________________